文献速递肝病

脂肪变性相关纤维化评估(SAFE)评分:一种在初级保健中识别低风险NAFLD的工具

The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care.
PubMed 文献 · Hepatology · 2022-05-24

研究基于NASH临床研究网络676例活检证实的NAFLD患者数据,构建并验证了SAFE评分以区分≥F2与F0/1纤维化。SAFE评分在测试集中曲线下面积≥0.80,高于FIB-4和NAFLD纤维化评分;SAFE为0时排除≥F2的阴性预测值分别为88%和92%。在NHANES III中,SAFE<0者25年生存率与无脂肪变性者相当(p=0.34),SAFE>100者调整后HR为1.53(p<0.01)。

要点

  • SAFE评分由年龄、BMI、糖尿病、血小板、AST、ALT和球蛋白构成。
  • SAFE为0时排除≥F2的阴性预测值在两个测试集中分别为88%和92%。
  • NHANES III中SAFE>100者调整后HR为1.53(p<0.01),与生存期缩短相关。

核心结论

  • SAFE评分使用广泛可得的变量来估算NAFLD患者的肝纤维化,可能用于初级保健中识别低风险NAFLD。

研究设计与样本

  • 从NASH临床研究网络观察性研究中提取活检证实的NAFLD患者数据(n=676),使用逻辑回归和机器学习方法构建预测模型以区分≥F2与F0/1。
  • 模型在FLINT试验参与者(n=280)和具有磁共振弹性成像数据的本地NAFLD患者(n=130)中测试。
  • 最终模型应用于NHANES III受检者(n=11,953)以分析其与长期死亡率的相关性。

主要发现

  • 多变量逻辑回归模型被选为SAFE评分,由年龄、体重指数、糖尿病、血小板、天冬氨酸和丙氨酸氨基转移酶以及球蛋白(总血清蛋白减去白蛋白)组成。
  • 在测试数据集中,该模型区分F0/1与≥F2的受试者工作特征曲线下面积≥0.80,一致高于FIB-4和NAFLD纤维化评分。
  • 在两个测试集中,SAFE为0时排除≥F2的阴性预测值分别为88%和92%。
  • 在NHANES III数据集中,SAFE<0的受试者长达25年的生存率与无脂肪变性者相当(p=0.34)。
  • SAFE评分升高与生存期缩短相关,SAFE>100的受试者调整后HR为1.53(p<0.01)。

关键数值与推荐

  • SAFE评分区分F0/1与≥F2的受试者工作特征曲线下面积≥0.80,高于FIB-4和NAFLD纤维化评分。
  • SAFE为0时排除≥F2的阴性预测值在两个测试集中分别为88%和92%。
  • NHANES III中SAFE<0者25年生存率与无脂肪变性者相当(p=0.34)。
  • NHANES III中SAFE>100者调整后HR为1.53(p<0.01)。

临床怎么用

  • SAFE评分可能用于初级保健中识别低风险NAFLD。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: NAFLD is common in primary care. Liver fibrosis stage 2 or higher (≥F2) increases future risk of morbidity and mortality. We developed and validated a score to aid in the initial assessment of liver fibrosis for NAFLD in primary care. METHODS: Data from patients with biopsy-proven NAFLD were extracted from the NASH Clinical Research Network observational study ( n = 676). Using logistic regression and machine-learning methods, we constructed prediction models to distinguish ≥F2 from F0/1. The models were tested in participants in a trial ("FLINT," n = 280) and local patients with NAFLD with magnetic resonance elastography data ( n = 130). The final model was applied to examinees in the National Health and Nutrition Examination Survey (NHANES) III ( n = 11,953) to correlate with long-term mortality. RESULTS: A multivariable logistic regression model was selected as the Steatosis-Associated Fibrosis Estimator (SAFE) score, which consists of age, body mass index, diabetes, platelets, aspartate and alanine aminotransferases, and globulins (total serum protein minus albumin). The model yielded areas under receiver operating characteristic curves ≥0.80 in distinguishing F0/1 from ≥F2 in testing data sets, consistently higher than those of Fibrosis-4 and NAFLD Fibrosis Scores. The negative predictive values in ruling out ≥F2 at SAFE of 0 were 88% and 92% in the two testing sets. In the NHANES III set, survival up to 25 years of subjects with SAFE < 0 was comparable to that of those without steatosis ( p = 0.34), whereas increasing SAFE scores correlated with shorter survival with an adjusted HR of 1.53 ( p < 0.01) for subjects with SAFE > 100. CONCLUSION: The SAFE score, which uses widely available variables to estimate liver fibrosis in patients diagnosed with NAFLD, may be used in primary care to recognize low-risk NAFLD.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Sripongpun P, Kim WR, Mannalithara A, et al. The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care. Hepatology. 2022. PMID: 35477908. doi:10.1002/hep.32545

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。